$23.27
0.17%
NYSE, Nov 28, 09:30 pm CET
ISIN
US28414H1032
Symbol
ELAN

Elanco Animal Health, Inc. Stock price

$23.27
+1.15 5.20% 1M
+9.87 73.66% 6M
+11.16 92.16% YTD
+10.14 77.23% 1Y
+11.12 91.52% 3Y
-7.32 23.93% 5Y
-12.73 35.36% 10Y
-12.73 35.36% 20Y
NYSE, Closing price Fri, Nov 28 2025
-0.04 0.17%
ISIN
US28414H1032
Symbol
ELAN
Industry

Key metrics

Basic
Market capitalization
$11.6b
Enterprise Value
$15.1b
Net debt
$3.5b
Cash
$505.0m
Shares outstanding
496.8m
Valuation (TTM | estimate)
P/E
332.4 | 25.3
P/S
2.5 | 2.5
EV/Sales
3.3 | 3.2
EV/FCF
41.7
P/B
1.7
Financial Health
Equity Ratio
48.3%
Return on Equity
5.5%
ROCE
2.0%
ROIC
-4.7%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$4.6b | $4.7b
EBITDA
$775.0m | $900.0m
EBIT
$241.0m | $678.2m
Net Income
$36.0m | $457.8m
Free Cash Flow
$362.0m
Growth (TTM | estimate)
Revenue
3.1% | 5.8%
EBITDA
-1.6% | 15.7%
EBIT
-4.7% | 170.2%
Net Income
-82.4% | 35.5%
Free Cash Flow
-2.7%
Margin (TTM | estimate)
Gross
55.0%
EBITDA
16.9% | 19.2%
EBIT
5.3%
Net
0.8% | 9.8%
Free Cash Flow
7.9%
More
EPS
$0.1
FCF per Share
$0.7
Short interest
6.3%
Employees
9k
Rev per Employee
$480.0k
Show more

Is Elanco Animal Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Elanco Animal Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

16x Buy
76%
5x Hold
24%

Analyst Opinions

21 Analysts have issued a Elanco Animal Health, Inc. forecast:

Buy
76%
Hold
24%

Financial data from Elanco Animal Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,591 4,591
3% 3%
100%
- Direct Costs 2,068 2,068
2% 2%
45%
2,523 2,523
4% 4%
55%
- Selling and Administrative Expenses 1,392 1,392
7% 7%
30%
- Research and Development Expense 356 356
4% 4%
8%
775 775
2% 2%
17%
- Depreciation and Amortization 534 534
0% 0%
12%
EBIT (Operating Income) EBIT 241 241
5% 5%
5%
Net Profit 36 36
82% 82%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Elanco Animal Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Elanco Animal Health, Inc. Stock News

Neutral
PRNewsWire
5 days ago
MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Deve...
Positive
Reuters
10 days ago
The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.
Neutral
PRNewsWire
10 days ago
EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in feline innovation Action reinforces the FDA's commitment to act swiftly against emerging animal health th...
More Elanco Animal Health, Inc. News

Company Profile

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Head office United States
CEO Jeffrey Simmons
Employees 9,225
Founded 1954
Website www.elanco.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today